Jacqueline C. Barrientos, MD, MS

Mount Sinai Comprehensive Cancer Center

N/A

Poster(s):

• 1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry

• 1226 - Outcomes of Tixagevimab/cilgavimab pre-exposure prophylaxis in Chronic lymphocytic leukemia patients- a single center experience

• 2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.

• 3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)